Brivaracetam
Brivaracetam. Newer SV2A ligand — same target as levetiracetam but ~20× higher affinity + better lipid solubility for faster CNS penetration. Used… Oral half-life 8 h.
Newer SV2A ligand — same target as levetiracetam but ~20× higher affinity + better lipid solubility for faster CNS penetration. Used for partial-onset seizures with potentially better psychiatric tolerability than levetiracetam.
PK: THE STORED HALF-LIFE WAS A RANDOMISATION RATIO. The cited abstract says "eliminated (t(1/2) 7-8 h)", and the only 9 in it is "or placebo (9 : 3)", the active-to-placebo allocation. The upper stated endpoint, 8 h, is now carried and is independently corroborated. F 1 was not measured in the cited paper, which has no intravenous arm at all; it is re-cited to Stockis 2016 (PMID:27346728), a five-period crossover in 25 participants that DOES include a 100 mg intravenous bolus and found bioequivalence with the tablets — which legitimises the intravenous row at the same time. Honest caveat: that study reports bioequivalence confidence limits rather than a point estimate, so F of 1 reads as an exposure ratio within 0.80 to 1.25 rather than a measured unity. Complete absorption and low protein binding are separately confirmed. V 40 L is dropped as unstated — the cited paper says only that volume was "slightly lower than total body water" — which leaves the resolver default, and that default happens to sit close to the qualitative description. ka 1.4 dropped against a stated time to peak of about 2 h.
Pharmacokinetics
- Oral — t½ 8 h · F 100%
- IV — t½ 8 h · F 100%
Sources: PMID:18341673, PMID:27346728, PMID:17908923